Amgen Stock - Dividend paid as analysts hold mixed views
17.06.2026 - 20:09:57 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 20:08 CET. Details in the imprint.
Amgen (US0311621009) has just moved past its latest quarterly cash return to shareholders. The biotech group recently paid its second-quarter 2026 dividend while analyst opinions on the stock remain mixed, according to several research summaries.
All news and analysis on Amgen stock
Track recent dividends, analyst updates and market data for Amgen in one place with our dedicated topic page.
Recent dividend and cash return
Amgen’s Board declared a cash dividend of $2.52 per share for the second quarter of 2026, payable on 06/05/2026 to shareholders of record as of 05/15/2026, according to an IR-based release dated 03/04/2026.
The payment keeps Amgen’s quarterly dividend at a high absolute level for a large-cap biotech. Based on a recent share price around the mid-$370s, the annualized payout of $10.08 per share implies a dividend yield in the low- to mid-2% range.
How analysts rate Amgen
Analyst views on Amgen remain cautious overall. A recent research summary notes that Wall Street’s consensus rating on the stock is Hold, with an average price target of about $354 per share, only modestly below where the stock has been trading in recent sessions.
Within that neutral stance, there are differing views. Mizuho Securities analyst Salim Syed, for example, recently maintained a Hold rating on Amgen with a price target of $303, according to a brief on healthcare stocks.
Consensus focus this Wednesday
Against this backdrop, today’s focus for Amgen stock is less on fresh headlines and more on where consensus sits. A Hold stance with a price target near the current quote suggests expectations are balanced between pipeline opportunity, patent expiries and integration of recent acquisitions.
Analyst models typically factor in Amgen’s established cash-generating franchises as well as investments in oncology, inflammation and biosimilars. For investors, the mix of a sizable dividend and moderate growth expectations defines much of the current narrative around the stock.
How Amgen makes its money
Amgen generates most of its revenue from branded biologic therapies such as Enbrel for inflammatory diseases and Prolia for osteoporosis, alongside oncology drugs like Kyprolis. The group also markets a growing portfolio of biosimilars and invests heavily in late-stage pipeline candidates.
Where the stock trades today
Amgen shares (US0311621009) trade on Nasdaq at $379.42 as of 06/17/2026, 18:00 UTC.
Key facts on Amgen stock
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867900
- Ticker: AMGN
- Venue: Nasdaq
- Price (as of 06/17/2026, 18:00 UTC): 379.42 USD
- Market cap: 203,000,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Standard & Poor's 500 index
- Next earnings date: 08/01/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
